Arabinose Is Sugar Moiety Patents (Class 536/27.4)
  • Patent number: 10815265
    Abstract: The present invention relates to a process for preparation of Regadenoson and polymorphs thereof. In particular, the present invention relates to a process for preparation of Regadenoson Form C.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: October 27, 2020
    Assignee: USV Private Limited
    Inventors: Laxmikant Narhari Patkar, Kamlesh Digambar Sawant, Harish Kashinath Mondkar, Tushar Anil Naik
  • Patent number: 9795154
    Abstract: The present invention relates to a method for preparing modified gum arabic comprising treating gum arabic with an enzyme selected from the group of glycosidases at a concentration of 1 to 1000 units of enzyme per gram of gum arabic, a modified gum arabic obtainable by said method, an emulsion comprising the modified gum arabic and a beverage concentrate and ready-to-drink beverage comprising the emulsion.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: October 24, 2017
    Assignee: RUDOLF WILD GMBH & CO. KG
    Inventors: Thomas Heidebach, Matthias Sass, Axel De With
  • Publication number: 20140323712
    Abstract: A new polymorph of 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine (designated as polymorph E), characterized by an X-ray diffraction pattern of X-RPD showing the following reflections at 2 Theta=5.8°, 12.3°, 15.9°, 17.3°, 20.5°, 22.6°, 23.6°, 27.7°, and 29.2°, and further characterized by DSC showing marked endotherm in the range of 258 to 264° C.
    Type: Application
    Filed: June 27, 2013
    Publication date: October 30, 2014
    Applicant: Farmak, a.s.
    Inventors: Lubomir KVAPIL, Pavel HRADIL, Martin GREPL, Petr SLEZAR, Barbora DVORAKOVA
  • Patent number: 8648188
    Abstract: A process for making clofarabine comprising: fluorinating a compound of formula VII wherein each R4 is independently a hydroxy protecting group, OR6 is a leaving group, with a fluorinating agent in the presence of guanidine carbonate to give a compound of formula VIII: wherein R4 is as defined above; and deprotecting the compound of formula VIII to give the clofarabine.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: February 11, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Lijun Mei, Yung-Fa Chen
  • Publication number: 20120220762
    Abstract: A method is described for the manufacture of pure 2-fluoro-ara-adenine of Formula (I) from 2-fluoro-ara-adenine triacetate using potassium carbonate (K2CO3), wherein the 2-fluoro-ara-adenine has a reduced dimer contents, as well as the compound 2-fluoro-ara-adenine having a dimer contents of ?0.3%.
    Type: Application
    Filed: May 12, 2010
    Publication date: August 30, 2012
    Inventors: Mathias Berwe, Clemens Bothe, Joachim Rehse
  • Publication number: 20120149888
    Abstract: The present invention relates to synthesis, purification and methods to obtain high purity novel 2?-arabino-O-methyl nucleosides and the corresponding phosphoramidites of various arabinonucleoside bases and introduction of such units into defined sequence synthetic DNA and RNA. Various synthetic oligonucleotides, such as HIV integrase inhibitor 14-mer and thrombin binding oligonucleotide, thrombin-1, bearing ara-2?-omethyl modification have been synthesized. It is anticipated the oligonucleotides incorporating these monomers will exhibit biological activities related to antisense approach approach, design of better SiRNA's, diagnostic agents. Similarly, it is anticipated that oligonucleotides incorporating such novel nucleosides will be useful to develop therapeutic candidates designing stable G-quadruplexes and Aptamers for oligonucleotide structure, folding topology, evaluation of biochemical properties and design and develop as therapeutic agents.
    Type: Application
    Filed: February 23, 2010
    Publication date: June 14, 2012
    Inventors: Suresh C. Srivastava, Divya Pandey, Naveen P. Srivastava, Alok Srivastava
  • Publication number: 20120071418
    Abstract: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.
    Type: Application
    Filed: September 12, 2011
    Publication date: March 22, 2012
    Applicant: Epizyme, Inc.
    Inventors: Robert A. Copeland, Victoria M. Richon, Margaret D. Scott, Christopher J. Sneeringer, Kevin W. Kuntz, Sarah K. Knutson, Roy M. Pollock
  • Patent number: 8076302
    Abstract: A novel pyrimidine nucleoside derivative represented by the following formula (1) and a salt thereof, as well as a pharmaceutical composition comprising the same as an active ingredient have excellent antiviral properties and are useful as antiviral therapeutic agents: [wherein R represents a nitrogen-containing heterocyclic ring which may have any one of a C1-C3 alkyl group or a C1-C3 alkoxy group as a substituent, or a C1-C6 alkyl group which has one primary amino group as a substituent].
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: December 13, 2011
    Assignee: aRigen Pharmaceuticals, Inc.
    Inventors: Haruhiko Machida, Masaichi Yamamoto
  • Publication number: 20110053883
    Abstract: The present invention provides an agent that modulates physiological condition of pests, wherein the agent has an ability to modulate the activity of an insect c-Jun NH2-terminal kinase; a method for assaying pesticidal activity of a test substance, which comprises a step of measuring the activity of a c-Jun NH2-terminal kinase in a reaction system in which the c-Jun NH2-terminal kinase contacts with a test substance, and the like.
    Type: Application
    Filed: June 23, 2006
    Publication date: March 3, 2011
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Yasutaka Shimokawatoko, Mar Van De Craen, Irene Nooren, Sandra Turconi, Annelies Roobrouck, Wendy Maddelein
  • Publication number: 20110009607
    Abstract: The present invention provides a method for preparing a DNA fragment, in which a desired double-stranded DNA fragment having a sticky end is directly and easily obtained from an amplification product (an amplified fragment) after PCR without a restriction enzyme digestion. The method for preparing a DNA fragment having a sticky end of the present invention comprises: (i) a step of performing a PCR reaction using a template DNA and specific primers to obtain an amplified DNA fragment; and (ii) a step of performing a prescribed treatment on the amplified DNA fragment to dissociate a protecting group from the fragment.
    Type: Application
    Filed: March 10, 2009
    Publication date: January 13, 2011
    Inventors: Makoto Komiyama, Akinori Kuzuya, Keita Tanaka
  • Publication number: 20090202470
    Abstract: The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: July 26, 2005
    Publication date: August 13, 2009
    Applicant: Gilead Sciences, Inc.
    Inventors: Constantine G. Boojamra, Kuei-Ying Lin, Richard L. Mackman, David Y. Markevitch, Oleg V. Petrakosvsky, Adrian S. Ray, Lijun Zhang
  • Publication number: 20090156544
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
    Type: Application
    Filed: February 23, 2009
    Publication date: June 18, 2009
    Inventors: Elfatih Elzein, Rao Kalla, Thao Perry, Jeff Zablocki, Xiaofen Li
  • Publication number: 20090012037
    Abstract: The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: July 27, 2005
    Publication date: January 8, 2009
    Applicant: Gilead Science, Inc.
    Inventors: Constantine G. Boojamra, Kuei-Ying Lin, Richard L. Mackman, David Y. Markevitch, Oleg V. Petrakovsky, Adrian S. Ray, Lijun Zhang
  • Patent number: 7470784
    Abstract: 2-Chloro-9-(2-deoxy-2-fluoro-?-D-arabinofuranosyl)-9H-purin-6-amine is synthesized by reacting a 2-chloro-6-substituted purine with a protected and activated 2-deoxy-2-fluoro-D-arabinofiranose; and reacting with a base such as ammonia to provide 2-chloro-9-(2-deoxy-2-fluoro-?-D-arabinofuranosyl)-9H-purin-6-amine. When the purine reactant is substituted in the 6 position with a halogen, a reaction step with an alkoxide is carried out prior to the reaction with ammonia.
    Type: Grant
    Filed: August 16, 2005
    Date of Patent: December 30, 2008
    Assignee: Southern Research Institute
    Inventors: John A. Montgomery, Anita T. Fowler, John A. Secrist, III
  • Publication number: 20080145372
    Abstract: The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, Formula: (1); wherein: R1 is a substituted aryl or heteroaryl group bearing at least one nitro or azido group or is an optionally substituted benzoquinone, optionally substituted naphthoquinone or optionally substituted fused heterocycloquinone: R2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, aryl or heteroaryl; and R3 is selected such that R3NH2 represents a cytotoxic nucleoside analogue or an ester or phosphate ester prodrug of a cytotoxic nucleoside analogue, with the proviso that if R1 is an aryl group then R2 is not H.
    Type: Application
    Filed: September 26, 2005
    Publication date: June 19, 2008
    Applicants: ANGIOGENE, PHARMACEUTICALS LIMITED, THE GRAY LABORATORY CANCER RESEARCH TRUST
    Inventors: Peter David Davis, Matthew Alexander Naylor, Peter Thomson, Steven Albert Everett, Michael Richard Lacey Stratford, Peter Wardman
  • Patent number: 7361759
    Abstract: To provide a method for producing L-biopterin on a large industrial scale by using a reagent which is inexpensive and easy to handle, without requiring a use of any particular equipment or plants. A method for porducing a biopterin derivative represented by the formula (6): wherein R1 and R2, which are the same or different from each other, each represents a hydrogen atom, an alkyl group, or an aryl group, comprising: reacting a compound belonging to triacetoxy-5-deoxy-L-arabinose phenylhydrazones represented by the formula (4): wherein R1 and R2 are the same as defined above, with 6-hydroxy-2,4,5-triaminopyrimidine (5) under catalytic influence of a Lewis acid in an aqueous solvent.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: April 22, 2008
    Assignees: Shiratori Pharmaceutical Co., Ltd, Asubio Pharma Co., Ltd.
    Inventor: Shinnosuke Tazawa
  • Publication number: 20070276146
    Abstract: The present invention provides an adenine modified solid, ordered, mesoporous, bifunctional, organo-inorganic silica-based catalyst, its method of preparation and also a process for the production of cyclic carbonates of the formula hereinbelow wherein R?H, CH2Cl, CH3, C4H9, C6H11, C6H5
    Type: Application
    Filed: May 23, 2006
    Publication date: November 29, 2007
    Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Darbha Srinivas, Rajendra Srivastava, Paul Ratnasamy
  • Publication number: 20070270373
    Abstract: A2A agonists of formula (I) is provided, wherein R1, R2, R4, R5, X, Y, Z, n, p, and q are as described herein. Also provided are compositions comprising and methods of using compounds of formula (I).
    Type: Application
    Filed: May 17, 2007
    Publication date: November 22, 2007
    Inventors: Jayson M. Rieger, Robert D. Thompson
  • Patent number: 7291726
    Abstract: The present invention is directed to the process for the preparation of 2?-deoxy-2?-halo-?-L-arabinofuranosyl nucleosides, and in particular, 2?-deoxy-2?-fluoro-?-L-arabinofuranosyl thymine (L-FMAU), from L-arabinose, which is commercially available and less expensive than L-ribose or L-xylose, in ten steps. All of the reagents and starting materials are inexpensive and no special equipment is required to carry out the reactions.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: November 6, 2007
    Assignee: Bukwang Pharmaceuticals Ind Co., Ltd.
    Inventor: Marcos Sznaidman
  • Patent number: 7244717
    Abstract: The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs. In particular, the invention provides 5-aldehydo-uracil nucleosides and derivatives thereof, and methods of administration thereof to increase the virus mutation rate in a virally infected cell.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: July 17, 2007
    Assignee: Koronis Pharmaceuticals, Incorporated
    Inventors: Ling Li, Alexander Gall, Richard Daifuku
  • Patent number: 6949640
    Abstract: 2-Chloro-9-(2-deoxy-2-fluoro-?-D-arabinofuranosyl)-9H-purin-9-amine is synthesized by reacting a 2-chloro-6-substituted purine with a protected and activated 2-deoxy-2-fluoro-D-arabinofuranose; and reacting with a base such as ammonia to provide 2-chloro-9-(2-deoxy-2-fluoro-?-D-arabinofuranosyl)-9H-purin-6-amine. When the purine reactant is substituted in the 6 position with a halogen, a reaction step with an alkoxide is carried out prior to the reaction with ammonia.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: September 27, 2005
    Assignee: Southern Research Institute
    Inventors: John A. Montgomery, Anita T. Fowler, John A. Secrist, III
  • Patent number: 6949521
    Abstract: Pharmaceutical prodrug compositions are provided comprising azide derivatives of drugs which are capable of being converted to the drug in vivo. Azide derivatives of drugs having amine, ketone and hydroxy substituents are converted in vivo to the corresponding drugs, increasing the half-life of the drugs. In addition azide prodrugs are often better able to penetrate the blood-brain barrier than the corresponding drugs. Especially useful are azide derivatives of cordycepin, 2?-F-ara-ddI, AraA, acyclovir, penciclovir and related drugs. Useful azide prodrugs are azide derivatives of therapeutic alicyclic amines, ketones, and hydroxy-substituted compounds, including aralkyl, heterocyclic aralkyl, and cyclic aliphatic compounds, where the amine or oxygen moiety is on the ring, or where the amine or oxygen moiety is on an aliphatic side chain, as well as therapeutic purines and pyrimidines, nucleoside analogs and phosphorylated nucleoside analogs.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: September 27, 2005
    Assignees: The University of Georgia Research Foundation, Inc., Emory University
    Inventors: Chung K. Chu, Lakshmi P. Kotra, Konstantine Manouilov, Jinfa Du, Raymond Schinazi
  • Patent number: 6924271
    Abstract: The invention is directed to 3-?-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: August 2, 2005
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Devron R. Averett, Stephen E. Webber, Joseph R. Lennox, Erik J. Rueden
  • Patent number: 6894159
    Abstract: The present invention relates to a novel and improved process for preparing 2?-fluoro-5-methyl-?-L-arabinofuranosyluridine represented by formula (1) which shows anti-viral activity, especially potent anti-viral activity against hepatitis B-virus and Epstein-Barr virus:
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: May 17, 2005
    Assignee: The University of Georgia Research Foundation
    Inventors: Chung K. Chu, Jinfa Du, Yongseok Choi
  • Patent number: 6870048
    Abstract: The present invention is directed to the process for the preparation of 2?-deoxy-2?-halo-?-L-arabinofuranosyl nucleosides, and in particular, 2?-deoxy-2?-fluoro-?-L-arabinofuranosyl thymine (L-FMAU), from L-arabinose, which is commercially available and less expensive than L-ribose or L-xylose, in ten steps. All of the reagents and starting materials are inexpensive and no special equipment is required to carry out the reactions.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: March 22, 2005
    Assignee: Triangle Pharmaceuticals
    Inventor: Marcos Sznaidman
  • Publication number: 20040259833
    Abstract: This invention provides broad-spectrum antibiotics that are inhibitors of bacterial adenine DNA methyltransferases.
    Type: Application
    Filed: June 25, 2004
    Publication date: December 23, 2004
    Applicants: The Board of Trustees of the Leland Stanford Junior University, The Penn State Research Foundation
    Inventors: Stephen J. Benkovic, Lucille Shapiro, Stephen J. Baker, Daphne C. Wahnon, Mark Wall
  • Publication number: 20040254141
    Abstract: A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer.
    Type: Application
    Filed: March 8, 2004
    Publication date: December 16, 2004
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • Publication number: 20040038350
    Abstract: A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (−)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.
    Type: Application
    Filed: August 20, 2003
    Publication date: February 26, 2004
    Inventors: Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
  • Patent number: 6680382
    Abstract: The present invention provides for the preparation &bgr;-adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of a base and solvent. The present invention also provides for the stereoselective preparation of 2-deoxy-&bgr;-D-adenine nucleosides wherein a blocked 2-deoxy-&agr;-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative. The forgoing aspects of the present invention are utilized in the preparation of a clofarabine composition wherein the ratio of &bgr; to &agr;-anomer is at least 99:1.
    Type: Grant
    Filed: August 1, 2002
    Date of Patent: January 20, 2004
    Assignee: Ilex Products, Inc.
    Inventors: William E. Bauta, Brian D. Burke, Brian E. Schulmeier, William R. Cantrell, Jr., Dennis P. Lovett, Jose Puente
  • Patent number: 6579976
    Abstract: There can be provided an excellent industrial process for producing compounds having sugar-moiety hydroxyl groups or halogen atoms reduced in nucleic acids or in derivatives thereof by allowing O-thiocarbonyl derivatives of sugar-moiety hydroxyl groups or allowing halogenated derivatives in the sugar-moiety, in the nucleic acids or in derivatives thereof to react with any one of hypophosphorous acids (including salts thereof) and phosphites (esters) which are inexpensive, non-toxic and safely usable as radical reducing agents in industrial scale, in the presence of a radical reaction initiator. The process of the present invention is an industrially useful and highly safe process for reducing sugar-moiety hydroxyl groups and halogen atoms in nucleic acids or derivatives thereof (including nucleic acid-related compounds) at low costs.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: June 17, 2003
    Assignee: Ajinomoto Co., Inc.
    Inventors: Satoshi Takamatsu, Satoshi Katayama, Naoko Hirose, Kunisuke Izawa
  • Publication number: 20030060622
    Abstract: The present invention is directed to the process for the preparation of 2′-deoxy-2′-halo-&bgr;-L-arabinofuranosyl nucleosides, and in particular, 2′-deoxy-2′-fluoro-&bgr;-L-arabinofuranosyl thymine (L-FMAU), from L-arabinose, which is commercially available and less expensive than L-ribose or L-xylose, in ten steps. All of the reagents and starting materials are inexpensive and no special equipment is required to carry out the reactions.
    Type: Application
    Filed: March 29, 2002
    Publication date: March 27, 2003
    Inventor: Marcos Sznaidman
  • Publication number: 20030023078
    Abstract: 2-Chloro-9-(2-deoxy-2-fluoro-&bgr;-D-arabinofuranosyl)-9H-purin-9-amine is synthesized by reacting a 2-chloro-6-substituted purine with a protected and activated 2-deoxy-2-fluoro-D-arabinofuranose; and reacting with a base such as ammonia to provide 2-chloro-9-(2-deoxy-2-fluoro-&bgr;-D-arabinofuranosyl)-9H-purin-6-amine. When the purine reactant is substituted in the 6 position with a halogen, a reaction step with an alkoxide is carried out prior to the reaction with ammonia.
    Type: Application
    Filed: July 16, 2001
    Publication date: January 30, 2003
    Inventors: John A. Montgomery, Anita T. Fowler, John A. Secrist, III
  • Patent number: 6512107
    Abstract: The present invention relates to a novel and improved process for preparing 2′-fluoro-5-methyl-&bgr;-L-arabinofuranosyluridine represented by formula (I) which shows anti-viral activity, especially potent anti-viral activity against hepatitis B-virus and Epstein-Barr virus:
    Type: Grant
    Filed: July 23, 1998
    Date of Patent: January 28, 2003
    Assignee: The University of Georgia Research Foundation
    Inventors: Chung K. Chu, Jinfa Du, Yongseok Choi
  • Patent number: 6500946
    Abstract: Novel intermediates of nucleoside derivatives, of which the 6-position of the nucleic acid base moiety is substituted with a halogen atom, are produced. Using those novel intermediates, even substrates, of which the 3′-position of the saccharide moiety is deoxylated, can be substituted at the 2′-position at an extremely high yield. Specifically, by subjecting a 3′-deoxy derivative of inosine to 6-halogenation to give a 6-halide of the derivative, and then subjecting it to 2′-deoxylation/substitution with a fluorine atom or the like, followed by further subjecting it to substitution with an amino group, a hydroxyl group or any other intended substituent at the 6-positioned halogen atom, nucleoside derivatives are produced at a high yield.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: December 31, 2002
    Assignee: Ajinomoto Co., Inc.
    Inventors: Satoshi Takamatsu, Satoshi Katayama, Naoko Hirose, Kunisuke Izawa, Tokumi Maruyama
  • Patent number: 6403568
    Abstract: The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: wherein B represents a base selected from the group consisting of pyrimidine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: June 11, 2002
    Assignee: Yamasa Corporation
    Inventors: Hiroshi Ohrui, Shiro Shigeta, Eiichi Kodama, Haruhiko Machida, Satoru Kohgo, Hiroaki Mitsuya
  • Publication number: 20020062018
    Abstract: The present invention relates to a novel and improved process for preparing 2′-fluoro-5-methyl-&bgr;-L-arabinofuranosyluridine represented by formula (1) which shows anti-viral activity, especially potent anti-viral activity against hepatitis B-virus and Epstein-Barr virus: 1
    Type: Application
    Filed: July 23, 1998
    Publication date: May 23, 2002
    Inventors: CHUNG K. CHU, JINFA DU, YONGSEOK CHOI
  • Patent number: 6376470
    Abstract: The present invention is directed to polymeric-prodrug transport forms of the formula: wherein: G is a linear or branched, terminally functionalized polymer residue; Y1 is O, S, or NR1; M is X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═Y1); R1-5 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls; R6 is OR7 or N3, NH2, NO2 or CN, where R7 is selected from the same group which defines R1-5; R8-9 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, or R6; and a and n are each independently zero or a positive integer.
    Type: Grant
    Filed: September 23, 1999
    Date of Patent: April 23, 2002
    Assignee: Enzon, Inc.
    Inventors: Richard B. Greenwald, Yun Hwang Choe
  • Patent number: 6335322
    Abstract: wherein R is selected from the group consisting of elaidoyl, cis-eicosenoyl and trans-eicosenoyl; and pharmaceutical compositions comprising the Ara-C derivative.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: January 1, 2002
    Assignee: Norsk Hydro ASA
    Inventors: Finn Myhren, Bernt Børretzen, Are Dalen, Kjell Torgeir Stokke
  • Patent number: 6333315
    Abstract: The invention provides 4′-C-ethynyl purine nucleosides represented by formula [I]: wherein B represents a base selected from the group consisting of purine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: December 25, 2001
    Assignee: Yamasa Corporation
    Inventors: Hiroshi Ohrui, Eiichi Kodama, Satoru Kohgo, Hiroaki Mitsuya, Masao Matsuoka, Kenji Kitano
  • Patent number: 6291670
    Abstract: The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: wherein B represents a base selected from the group consisting of pyrimidine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: September 18, 2001
    Assignee: Yamasa Corporation
    Inventors: Hiroshi Ohrui, Shiro Shigeta, Eiichi Kodama, Haruhiko Machida, Satoru Kohgo, Hiroaki Mitsuya
  • Patent number: 6271212
    Abstract: Pharmaceutical prodrug compositions are provided comprising azide derivatives of drugs which are capable of being converted to the drug in vivo. Azide derivatives of drugs having amine, ketone and hydroxy substituents are converted in vivo to the corresponding drugs, increasing the half-life of the drugs. In addition azide prodrugs are often better able to penetrate the blood-brain barrier than the corresponding drugs. Especially useful are azide derivatives of cordycepin, 2′-F-ara-ddI, AraA, acyclovir, penciclovir and related drugs. Useful azide prodrugs are azide derivatives of therapeutic alicyclic amines, ketones, and hydroxy-substituted compounds, including aralkyl, heterocyclic aralkyl, and cyclic aliphatic compounds, where the amine or oxygen moiety is on the ring, or where the amine or oxygen moiety is on an aliphatic side chain, as well as therapeutic purines and pyrimidines, nucleoside analogs and phosphorylated nucleoside analogs.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: August 7, 2001
    Assignees: University of Georgia Research Foundation Inc., Emory University
    Inventors: Chung K. Chu, Lakshimi Kotra, Kostantine K. Manouilov, Jinfa Du, Raymond Schinazi
  • Patent number: 6258360
    Abstract: Prodrugs that are activated by and conjugated to a catalytic antibody conjugated to a moiety that binds to a tumor cell population are provided.
    Type: Grant
    Filed: October 18, 1994
    Date of Patent: July 10, 2001
    Assignee: IGEN International, Inc.
    Inventors: Reid von Borstel, Jan M. Casadei, Balreddy Kamireddy, John Henry Kenten, Mark T. Martin, Richard J. Massey, Andrew D. Napper, David M. Simpson, Rodger G. Smith, Richard C. Titmas, Richard O. Williams
  • Patent number: 6242429
    Abstract: Antiviral Ara-A derivatives having resistance to metabolism by adenosinedeaminase (ADA) are 2-substituted arabinosyladenine derivatives represented by the formula (I) and pharmaceutically acceptable salts and hydrates thereof: wherein Z is alkyl having at least 4 carbon atoms, alkenyl or alkynyl and R is hydrogen or lower alkyl. The compounds are useful as therapeutic or preventive agents for diseases infected by DNA virus such as herpes simplex virus (HSV), herpes zoster virus, cytomegalovirus (CMV), adenovirus, hepatitis virus or vaccinia virus. As compared with Ara-A, they not only show good activity in blood with an excellent sustaining property but also are capable of being orally administered without substantial loss of pharmaceutical effectiveness due to metabolism by ADA.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: June 5, 2001
    Assignee: Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Toshio Yamada, Koichi Yamanishi